scPharmaceuticalsNASDAQ: SCPH

scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2024 Earnings Call Transcript May 14, 2024 4:30 PM ET with Company Representatives PJ Kelleher - Investor Relations, John Tucker - CEO, Steve Parsons - Senior Vice President of Commercial, and Rachael Nokes - CFO. Conference Call Participants include Glen Santangelo from Jefferies, Stacy Ku from TD Cowen, Roanna Ruiz from Leerink Partners, Chase Knickerbocker from Craig-Hallum Capital, Naz Rahman from Maxim Group, and Douglas Tsao from HC Wainwright. The operator begins the call with a welcome message and instructions for participants.

SCPharmaceuticals, Inc. (SCPH) reported a quarterly loss of $0.36 per share, which was better than the expected loss of $0.45 per share according to the Zacks Consensus Estimate. This is higher than the loss of $0.30 per share reported in the same quarter last year.

scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript

BURLINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will participate in two upcoming investor conferences.

Q3 earnings report shows positive performance, with Furoscix net sales exceeding consensus estimates. scPharmaceuticals' progress in securing payer coverage and IDN agreements is driving confidence in its prospects. The company's healthy financial position and potential market opportunity for Furoscix make it an undervalued investment.

scPharmaceuticals Inc (NASDAQ:SCPH ) Q3 2023 Earnings Call Transcript November 8, 2023 4:30 PM ET Company Participants PJ Kelleher - LifeSci Advisors John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President, Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Nik Gasic - Leerink Partners Douglas Tsao - H.C. Wainwright Naz Rahman - Maxim Group Chase Knickerbocker - Craig-Hallum Capital Group Operator Thank you for standing by.

Positive FDA feedback for Furoscix's label expansion into chronic kidney disease signals the potential for significant market growth. Introduction of a higher concentration auto-injector formulation of Furoscix could reduce costs and enhance patient convenience. Q2 earnings show encouraging market momentum for Furoscix, with continued demand and growth in prescribers.

Today, we take our first look at scPharmaceuticals Inc., which has received positive analyst commentary but has a large short position in the stock. The company just launched its franchise product FUROSCIX in February of this year and management believes it has huge potential. Analysts expect sales to reach nearly $40 million in FY2024, but the company is projected to continue experiencing losses.

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants PJ Kelleher - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President, Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Glen Santangelo - Jefferies Stacy Ku - TD Cowen Doug Tsao - H.C. Wainwright Naz Rahman - Maxim Group Operator Good day and welcome to the scPharmaceuticals Second Quarter 2023 Earnings Conference Call.